Philips Zenition (family)
Philips's current mobile C-arm platform, replacing the Veradius family. Shared workflow and image-chain features with the fixed Azurion interventional platform, creating a unified user experience across hybrid and mobile use. Available in multiple detector-size and clinical-segment tiers.
History
- 2018 — Zenition launches as the Veradius successor.
- 2020s — full lineup extends across orthopedic / general / vascular / cardiac tiers; integration with Azurion-class workflow consolidates the Philips mobile / fixed line.
Variants
- Zenition 10 — entry, orthopedic / pain management.
- Zenition 30 — mid, general surgical.
- Zenition 50 — premium, vascular / cardiac.
- Zenition 70 — high-end, cardiovascular.
Shared platform characteristics
- Flat-panel detector across all variants — eliminates image-intensifier distortion at the periphery.
- Grid-controlled pulsed fluoroscopy for dose reduction.
- Azurion-class image processing on mid / premium tiers — visual continuity with the fixed cath / IR rooms.
- Compact design, tool-free positioning — drape-friendly OR ergonomics.
- ConnectOS-derived workflow consistent with Azurion.
Distinctive technology
- Cross-platform workflow consistency with Azurion — operator teams trained on the fixed-room platform see the same UI patterns on Zenition mobile.
- Pulsed-fluoro dose-reduction posture inherited from the Allura / Azurion image-processing lineage.
Market position
Mid-to-premium mobile C-arm tier. Direct competitors:
- GE OEC 9800 MD / 9900 Elite — global market leader.
- Siemens Cios Alpha — flat-panel premium competitor.
- Ziehm Vision RFD — flat-panel premium competitor.
Predecessor
- Philips Veradius family (mid-generation flat-panel).
- BV Pulsera / BV Endura (legacy image-intensifier line).
Refurb posture
- Newer line — refurb supply small as installed base is younger; OEM service contracts dominate the operating-cost structure.
- Tier (10 / 30 / 50 / 70) is a meaningful price-determining variable; clinical capability scales with tier.
- Software / control-system version affects supportability and dose-reduction posture.